METASTATIC BREAST CANCER

This study tests a drug called Trastuzumab-Deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors and control the cancer. Participants receive the drug intravenously, and doctors monitor tum…

This phase 2 study tests whether adding the experimental drug ipatasertib to standard hormone therapy and a targeted drug can help people with a specific type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. The study includes 57 participants whose …

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other cancer medicines in people with HER2-positive breast cancer that has spread. The goal is to find safe doses and see how well the combinations shrink tumors. About 245 adults with advanced or metasta…

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a certain type of advanced breast cancer (HR+/HER2-) live longer without the disease getting worse. About 110 participants will receive either the drug alone or the combination. Th…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other cancer medicines in people whose breast cancer has spread and has low levels of a protein called HER2. The main goals are to see if the combinations are safe and to find the best doses. About 138 ad…

This study tests a new approach for people with a specific genetic type of advanced breast cancer (HRD-positive, HER2-negative). After initial chemotherapy, one group switches to a daily pill combination (fluorizoparib + apatinib) for long-term control, while the other group stay…

This study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) is safe and effective for people with triple-negative breast cancer that has spread to other parts of the body. About 50 adults with advanced disease are participating. The goa…

This phase 3 trial tests whether giving denosumab every 12 weeks is as effective as the standard every 4 weeks at preventing bone complications (like fractures or need for radiation) in people with metastatic breast or prostate cancer that has spread to the bone. About 1380 parti…

This study looks at whether people with HER2-positive metastatic breast cancer who have had an excellent response to treatment (cancer controlled for 3+ years) can safely stop their anti-HER2 therapy. Researchers will monitor how long it takes for the cancer to progress in those …

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) in people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. The trial includes 14 adults whose…

This study tests a combination of two drugs, niraparib and trastuzumab, in people with metastatic HER2-positive breast cancer. The goal is to see if the combo is safe and can shrink tumors or slow the disease. About 46 women with advanced cancer that has spread will take part.

This study compares a new drug, sacituzumab govitecan, to standard chemotherapy in people with a common type of advanced breast cancer (HR+/HER2-) that has not responded to at least two prior chemotherapies. The goal is to see if the new drug can slow cancer growth or improve sur…

This study tests whether continuing the targeted therapy palbociclib while switching to a different hormone therapy (fulvestrant) can help people with a certain type of advanced breast cancer (hormone receptor-positive, HER2-negative) whose disease has worsened despite initial tr…

This study tests three drug combinations for people with a common type of advanced breast cancer (ER+/HER2-) that has stopped responding to initial hormone therapy. About 220 participants will receive either fulvestrant alone, fulvestrant plus palbociclib, or fulvestrant plus pal…

This study tests a new drug, DB-1303, against standard chemotherapy for people with a specific type of advanced breast cancer (HER2-low, HR-positive) that has stopped responding to hormone therapy. The goal is to see if DB-1303 can delay cancer growth better than chemo. About 541…

This study tests whether a new drug called RPH-051 works as well as the approved drug Perjeta when both are given with standard chemotherapy for HER2-positive breast cancer that has spread or cannot be removed by surgery. About 246 participants will receive either RPH-051 or Perj…

This study tests a combination of special immune cells (HER2 BATs) that target breast cancer cells, plus the drug pembrolizumab, in women with metastatic breast cancer. The goal is to find a safe dose and see if the treatment shrinks tumors. About 22 women will take part in two p…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This study tests a drug called abemaciclib, given alone or with tamoxifen, in women with a certain type of advanced breast cancer (HR+, HER2-) that has spread and stopped responding to previous treatments. The goal is to see if the combination can slow cancer growth. About 234 wo…

This study tests whether adding a high-dose, precise type of radiation called SBRT to standard treatments (like hormone therapy or chemotherapy) can delay cancer progression in people with solid tumors that have spread to 1 to 5 spots in the bones. It includes adults up to age 75…

This study tests a drug called olaparib in people with metastatic breast cancer that has spread beyond the breast. Participants must have a specific gene mutation that makes their cancer cells less able to repair DNA damage. The goal is to see if olaparib can shrink tumors or slo…

This study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific type of advanced breast cancer (ER-positive, HER2-low, non-luminal A). The trial was withdrawn before enrolling any participants, so no results are …

This study tests whether a very low-carb (ketogenic) diet, a low-carb diet, or the diabetes drug canagliflozin can prevent high blood sugar caused by the cancer drug alpelisib. The goal is to see if controlling blood sugar helps the cancer treatment work better in people with adv…

This study tests a drug called elacestrant in 61 people with a common type of advanced breast cancer (ER+/HER2-). Participants have not received a specific class of drugs (CDK4/6 inhibitors) before. The goal is to see if elacestrant can slow or stop cancer growth over 6 months.

This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it is …

This early-phase study tests a vaccine (PVX-410) alone or with the immunotherapy drug pembrolizumab in 20 women with metastatic triple negative breast cancer who have a specific genetic marker (HLA-A2). The goal is to see if the vaccine safely boosts the immune system to fight th…

This study gives ongoing access to ribociclib for people with metastatic breast cancer who are already benefiting from it in a previous Novartis study. It aims to monitor long-term safety and side effects. About 134 participants will continue their treatment and be followed for c…

This study looks at whether a 9-month, personalized exercise plan can lessen cancer-related fatigue and improve quality of life in 357 people with stage IV breast cancer. Participants follow a structured exercise routine and wear an activity tracker. The goal is to see if exercis…

This study looks at whether a blood test that tracks tumor DNA can help doctors switch treatments earlier in people with stage IV breast cancer. The goal is to see if acting on this early signal can keep the cancer under control longer than waiting for scans to show growth. About…

This study looks at medical records from nearly 8,000 people with HER2-altered metastatic breast cancer in the United States. The goal is to understand how these patients are treated in everyday practice and how long they live. No new treatments are tested; instead, researchers g…

This study looks at whether eating only during certain hours of the day (time-restricted eating) can help prevent frailty in people over 55 who are on hormone therapy for prostate cancer. Frailty means losing strength and independence. The study will test if this eating pattern h…

This study looks at the 'time toxicity' of cancer—how much time people with advanced breast or ovarian cancer spend on care tasks like appointments, travel, and managing symptoms. About 80 participants will use a smartphone app for 28 days to track their activities and daily well…

This study looks at how the drug tucatinib enters and works in HER2+ brain tumors before they are surgically removed. Researchers want to understand why some cancer cells stop responding to treatment. Nine adults with HER2+ breast, lung, stomach, or colorectal cancer that has spr…

This study uses a special type of PET/CT scan called FLT to see how active breast cancer tumors are before and during treatment with two drugs (ribociclib and paclitaxel). About 20 adults with metastatic breast cancer that has spread beyond the liver and bones will take part. The…

This study is observing whether a specific blood test that looks for cancer cells can help doctors make better treatment decisions for people with metastatic breast cancer. It involves 65 patients who will have blood drawn and their treatment monitored. The goal is to see if this…